Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/25/26
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026GlobeNewsWire • 02/11/26
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)Seeking Alpha • 01/28/26
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value CreationGlobeNewsWire • 12/11/25
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDSGlobeNewsWire • 12/08/25
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could HelpSeeking Alpha • 11/07/25
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire • 11/05/25
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic MalignanciesBusiness Wire • 11/03/25
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/29/25
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025Business Wire • 10/27/25
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 10/23/25
Geron Corporation: Early Momentum, Strong Leadership Plus Clear Path To Growth - Why I BuySeeking Alpha • 10/23/25
Geron Corporation Announces Executive Leadership Transitions and AppointmentsGlobeNewsWire • 10/13/25
GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/13/25